Brokerages forecast that Sarepta Therapeutics Inc (NASDAQ:SRPT) will post sales of $57.39 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Sarepta Therapeutics’ earnings, with the lowest sales estimate coming in at $57.28 million and the highest estimate coming in at $57.69 million. Sarepta Therapeutics posted sales of $5.42 million in the same quarter last year, which suggests a positive year over year growth rate of 958.9%. The business is expected to report its next quarterly earnings report after the market closes on Tuesday, February 27th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full year sales of $57.39 million for the current financial year, with estimates ranging from $154.59 million to $155.00 million. For the next year, analysts expect that the business will post sales of $299.17 million per share, with estimates ranging from $293.29 million to $302.60 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Sarepta Therapeutics.

SRPT has been the topic of several analyst reports. HC Wainwright set a $75.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Oppenheimer reaffirmed a “buy” rating and set a $76.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Robert W. Baird reaffirmed a “buy” rating and set a $101.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, October 17th. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 25th. Finally, Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Monday, October 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $64.65.

Sarepta Therapeutics (SRPT) traded down $2.03 during mid-day trading on Tuesday, hitting $55.14. 4,489,104 shares of the stock traded hands, compared to its average volume of 1,800,000. The stock has a market cap of $3,560.00, a price-to-earnings ratio of -27.03 and a beta of 1.49. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics has a 1 year low of $26.26 and a 1 year high of $68.90.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares in the company, valued at $745,181.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 9.60% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its stake in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares in the last quarter. Advisor Group Inc. grew its stake in shares of Sarepta Therapeutics by 3.2% during the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 326 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Sarepta Therapeutics by 0.8% during the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after purchasing an additional 818 shares in the last quarter. Benchmark Capital Advisors grew its stake in shares of Sarepta Therapeutics by 4.2% during the fourth quarter. Benchmark Capital Advisors now owns 21,250 shares of the biotechnology company’s stock worth $1,182,000 after purchasing an additional 850 shares in the last quarter. Finally, C WorldWide Group Holding A S grew its stake in shares of Sarepta Therapeutics by 0.8% during the third quarter. C WorldWide Group Holding A S now owns 122,469 shares of the biotechnology company’s stock worth $5,555,000 after purchasing an additional 941 shares in the last quarter. Institutional investors and hedge funds own 81.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/11/57-39-million-in-sales-expected-for-sarepta-therapeutics-inc-srpt-this-quarter.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.